Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services
he CMO Gallus BioPharmaceutical has acquired the biologics CMO Laureate Biopharmaceutical Services.
Gallus BioPharmaceuticals, a St. Louis-based CMO has acquired Laureate Biopharmaceutical Services, a biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development and clinical drug-substance-manufacturing capacity and adds full protein characterization, testing, and clinical fill-finish capability. With the acquisition, Gallus has two centers of excellence. The Princeton site is a Center of Excellence for process development and manufacture of clinical-stage products, including fill-finish, and the St. Louis site is a Center of Excellence for process development and clinical and commercial manufacture of biopharmaceutical products.
Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.
Source: Gallus BioPharmaceuticals
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
